Biofrontera announces preliminary revenue for Q1 2021
08 avr. 2021 10h30 HE
|
Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
31 mars 2021 10h12 HE
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
31 mars 2021 03h40 HE
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
26 févr. 2021 09h20 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera submits study report of pharmacokinetics study to FDA
24 févr. 2021 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares
23 févr. 2021 19h54 HE
|
Biofrontera AG
NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Leverkusen, Germany, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
02 févr. 2021 10h35 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary revenue figures for the full year 2020
08 janv. 2021 09h35 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Cologne Higher Regional Court grants approval of capital increase
07 janv. 2021 11h45 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
07 déc. 2020 09h10 HE
|
Biofrontera AG
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö,...